Servier to buy Day One Biopharma for $2.5 billion in tumor treatment push [Yahoo! Finance]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Yahoo! Finance
Servier has ?offered $21.50 per share in cash, a premium of 68% to the stock's last close. ?Shares of Day One jumped 65% in morning trade. The deal will give the company access to Day One's Ojemda, the only U.S. Food and Drug Administration-approved monotherapy for pediatric low-grade glioma, the most ?common form of brain ?tumor in children. Servier already sells adult glioma drug Voranigo and the deal strengthens its presence in the ?space. The company has been pushing to build its rare cancer portfolio to meet its target of 10 billion euros ($11.58 billion) in annual ?revenue by ?2030. Ojemda was approved in 2024 ?in patients whose tumors progressed ?after prior treatment. It is now being tested as a first-line therapy, with trial results expected in the second half of 2027. Wedbush analyst Robert Driscoll called Day One "an attractive take-out candidate", pointing to the successful launch of Ojemda and potential for future sales ?if the drug is approved in the ?frontline
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting [Yahoo! Finance]Yahoo! Finance
- Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc. [Yahoo! Finance]Yahoo! Finance
- Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now [Yahoo! Finance]Yahoo! Finance
- Beacon Therapeutics appoints Ryan Robinson as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 2/4/26 - Beat
NVS
Sec Filings
- 2/12/26 - Form 144
- 2/9/26 - Form 144
- 2/4/26 - Form S-8
- NVS's page on the SEC website